2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
66
Lymphoma
35
Neutropenia
30
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Non-Hodgkin
18
Neoplasms
15
Carcinoma, Non-Small-Cell Lung
14
Ovarian Neoplasms
13
Hodgkin Disease
13
Sarcoma
11
Multiple Myeloma
11
Lymphoma, Mantle-Cell
10
Lymphoma, Follicular
10
Leukemia
10
Burkitt Lymphoma
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lung Neoplasms
9
Triple Negative Breast Neoplasms
8
Rhabdomyosarcoma
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Chemotherapy-induced Neutropenia
7
Central Nervous System Neoplasms
6
Breast Neoplasms, Male
6
Testicular Neoplasms
5
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Lymphoma, B-Cell, Marginal Zone
5
Febrile Neutropenia
5
Fallopian Tube Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
Clear all
NCT02582697
2025-06-15
P3BEP
University of Sydney
Phase 3
Recruiting
500 enrolled
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled